Coeptis Therapeutics (NASDAQ:COEP) Trading Down 2.1% – Here’s Why

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) shares were down 2.1% on Monday . The company traded as low as $10.85 and last traded at $11.06. Approximately 24,612 shares were traded during mid-day trading, a decline of 48% from the average daily volume of 47,321 shares. The stock had previously closed at $11.30.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Coeptis Therapeutics in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Coeptis Therapeutics presently has an average rating of “Sell”.

Coeptis Therapeutics Price Performance

The company has a market capitalization of $69.60 million, a PE ratio of -3.76 and a beta of -0.49. The stock has a 50 day moving average price of $12.35 and a two-hundred day moving average price of $14.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.16 and a current ratio of 4.16.

Coeptis Therapeutics (NASDAQ:COEP) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.12) earnings per share for the quarter. The business had revenue of $0.86 million for the quarter. Coeptis Therapeutics had a negative net margin of 803.96% and a negative return on equity of 110.89%.

Hedge Funds Weigh In On Coeptis Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP acquired a new position in shares of Coeptis Therapeutics during the 4th quarter valued at about $259,000. State Street Corp boosted its position in Coeptis Therapeutics by 35.0% during the fourth quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after purchasing an additional 6,962 shares during the period. Geode Capital Management LLC grew its holdings in Coeptis Therapeutics by 12.6% during the fourth quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after purchasing an additional 4,721 shares during the last quarter. Steward Partners Investment Advisory LLC raised its position in shares of Coeptis Therapeutics by 100.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares during the period. Finally, Yorkville Advisors Global LP acquired a new stake in shares of Coeptis Therapeutics in the third quarter worth $140,000. 13.88% of the stock is currently owned by institutional investors.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.